Kubota Kiyoshi, Yoshizawa Masaki, Takahashi Satoru, Fujimura Yoshiaki, Nomura Hiroko, Kohsaka Hitoshi
NPO Drug Safety Research Unit Japan, 6-2-9-2F, Soto-Kanda, Chiyoda-ku, Tokyo, 101-0021, Japan.
Department of Rheumatology, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
BMC Musculoskelet Disord. 2021 Apr 22;22(1):373. doi: 10.1186/s12891-021-04259-9.
An administrative database covering a whole population such as the national database in Japan may be used to estimate the nationwide prevalence of diseases including rheumatoid arthritis (RA) when a well-validated definition of the disease is available. In Japan, the record linkage between the administrative database and medical charts in hospitals is strictly prohibited. A "hospital-based" validation study is one of few possible validation studies where claims kept inside the study hospital are rearranged into the database structure.
We selected random samples of 19,734 patients from approximately 1.6 million patients who received medical care between February 2018 and January 2019 in one of the 64 hospitals of the Tokushukai Medical Group. We excluded patients whose observation period was less than 365 days and identified 334 patients who met the definition of "possible cases of RA" whose medical charts were then independently evaluated by two rheumatologists. In a sensitivity analysis, we assessed bias due to misclassifying some patients with RA who did not meet the definition of "possible cases of RA" as a patient with no RA.
The kappa coefficient between the two rheumatologists was 0.80. The prevalence of RA in the study population was estimated to be 0.56%. We found that [condition code of RA] and ([any disease-modifying antirheumatic drug] or [oral corticosteroid with no systemic autoimmune diseases (other than RA) and no polymyalgia rheumatica]) had a relatively high sensitivity (approximately 73%) and a high positive predictive value (approximately 80%). In a sensitivity analysis, we found that when some patients with RA who did not meet the definition of "possible cases of RA" were misclassified as a patient with no RA, then this would lead to underestimation of the prevalence of the definition-positive patients and the adjusted prevalence.
We recommend using the claims-based definition of RA (found in the current validation study) to estimate the prevalence of RA in Japan. We also suggest estimating the adjusted prevalence using the quantitative bias analysis method, since the prevalence of the disease in the "hospital-based" validation study is different from that in the administrative database.
The current study is not a clinical trial and hence not subject to trial registration.
当有经过充分验证的疾病定义时,像日本的全国数据库这样涵盖整个人口的行政数据库可用于估计包括类风湿关节炎(RA)在内的疾病的全国患病率。在日本,严格禁止行政数据库与医院病历之间的记录关联。“基于医院”的验证研究是少数可行的验证研究之一,即将研究医院内部保存的索赔数据重新整理成数据库结构。
我们从德洲会医疗集团64家医院之一在2018年2月至2019年1月期间接受医疗护理的约160万名患者中随机抽取了19734名患者样本。我们排除了观察期少于365天的患者,并确定了334名符合“可能的RA病例”定义的患者,然后由两名风湿病学家对其病历进行独立评估。在敏感性分析中,我们评估了由于将一些不符合“可能的RA病例”定义的RA患者误分类为无RA患者而导致的偏差。
两名风湿病学家之间的kappa系数为0.80。研究人群中RA的患病率估计为0.56%。我们发现,[RA的疾病编码]以及([任何改善病情抗风湿药物]或[无全身性自身免疫性疾病(除RA外)且无风湿性多肌痛的口服糖皮质激素])具有相对较高的敏感性(约73%)和较高的阳性预测值(约80%)。在敏感性分析中,我们发现,当一些不符合“可能的RA病例”定义的RA患者被误分类为无RA患者时,这将导致对定义阳性患者的患病率和调整后患病率的低估。
我们建议使用基于索赔的RA定义(在当前验证研究中发现)来估计日本RA的患病率。我们还建议使用定量偏差分析方法估计调整后的患病率,因为“基于医院”的验证研究中该疾病的患病率与行政数据库中的患病率不同。
本研究不是临床试验,因此无需进行试验注册。